Drug research

Renal Autologous Cell Therapy (REACT)

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Rilparencel; rilparencel

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)NCT05018416	Prokidney	Phase 2	Completed	2025-05-20Actual
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney DiseaseNCT03270956	Prokidney	Phase 2	Completed	2022-11-17Actual
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney DiseaseNCT02836574	Prokidney	Phase 2	Completed	2023-12Actual

ProkidneyCompletedPrimary completion: 2025-05-20 · Actual

Trial details

ProkidneyCompletedPrimary completion: 2022-11-17 · Actual

Trial details

ProkidneyCompletedPrimary completion: 2023-12 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.